Ribomic, Inc.

9 articles about Ribomic, Inc.

• RIBOMIC Announces Completion of IND Submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia

  4/19/2022

  RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that it submitted an Investigational New Drug Application (IND) for an observational study to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

• RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration

  3/23/2022

  RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the results from the investigator sponsored trial (IST), TEMPURA, along with updated data from its TOFU and RAMEN studies with RBM-007, an investigational anti-fibroblast growth factor-2 aptamer, in wet age-related macular degeneration (wAMD).

• RIBOMIC Announces Preliminary Topline Data From Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration

  12/28/2021

  RIBOMIC, Inc. today announced the topline data from the Phase 2 TOFU study of RBM-007 in patients with Wet Age-Related Macular Degeneration (wAMD).

• RIBOMIC Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting

  9/30/2021

  RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the presentation of preliminary interim results from the ongoing two Phase 2 studies, TOFU and the RAMEN extension study in patients with Wet Age-Related Macular Degeneration (wAMD) by Dr. Raj Maturi at the 54th Annual Scientific Meeting of the Retina Society, Chicago, USA.

• RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial for Achondroplasia

  7/15/2020

  RIBOMIC, Inc. , a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (TOKYO:4591), today announced that the first subject in cohort 1 was administered with RBM-007 subcutaneously in Phase 1 clinical trial in Japan. This represen

• RIBOMIC Enters License Agreement with AJU Pharma for RBM-007 in Age-related Macular Degeneration

  3/17/2020

  RIBOMIC Inc. , today announced that RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Sout

• RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration

  2/19/2020

  RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.

• RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration

  6/17/2019

  RBM-007 was well-tolerated with no dose-limiting toxicities, no systemic or ocular serious adverse events.

• Archemix Corporation Expands Collaboration with Ribomic, Inc. for Rights to Develop Aptamer Therapeutics for Multiple Drug Targets; Archemix Will Receive an Upfront Payment of $6 Million with a Total Potential Payment of $200M

  8/8/2008